Drugs /

kn026

Back to Drugs List

Overview

NCI Definition [1]:
An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, anti-HER-2 bispecific antibody KN026 simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2, thereby inhibiting HER-2 heterodimerization and prevents the activation of HER-2 signaling pathways. By binding to HER-2, KN026 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in proliferation, differentiation and survival.

Clinical Trials

View Clinical Trials for kn026

Kn026 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating kn026, 1 is phase 1 (1 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for kn026 clinical trials.

Breast carcinoma and gastric carcinoma are the most common diseases being investigated in kn026 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Kn026
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating kn026 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
her2 bispecific antibody kn026, anti-her2 heterodimeric antibody kn026, anti-her-2 bispecific antibody kn026, kn 026, kn-026
Drug Target(s) [2]:
ERBB2
NCIT ID [1]:
C162577

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.